Is Cefdinir a Good Antibiotic for Sinus Infections?

Cefdinir is an effective antibiotic for bacterial sinus infections, but it is not the top choice. Treatment guidelines place it in a second tier of predicted effectiveness, with cure rates in the range of 83 to 88 percent, compared with roughly 90 percent or higher for first-line options like amoxicillin-clavulanate and fluoroquinolones. That said, cefdinir earns a real role in two common scenarios: mild sinus infections in patients who haven’t taken antibiotics recently, and cases where a penicillin allergy rules out the usual go-to drugs.

Where Cefdinir Ranks Among Sinus Infection Antibiotics

Sinus infection treatment guidelines group antibiotics into effectiveness tiers based on how well they cover the bacteria most often responsible: Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. At the top sit respiratory fluoroquinolones, injectable ceftriaxone, and high-dose amoxicillin-clavulanate, all with predicted efficacy in the 90 to 92 percent range. Cefdinir falls into the next group, alongside regular-dose amoxicillin, cefuroxime, and a few other oral cephalosporins, with predicted efficacy of 83 to 88 percent.¹ That gap isn’t dramatic, but it means your doctor will usually reach for amoxicillin or amoxicillin-clavulanate first if you can tolerate them.

In practice, cefdinir is listed among the recommended initial choices for adults and children with mild disease who haven’t been on antibiotics in the previous four to six weeks. For children with mild disease who have a penicillin rash (not the life-threatening type of allergy), guidelines specifically note that cefdinir is preferred among the cephalosporin alternatives because of its high patient acceptance, largely due to its palatable liquid formulation.¹

Head-to-Head Trial Results

Several randomized trials have directly compared cefdinir against the antibiotics doctors rely on most for sinusitis. In a large trial of nearly 570 patients with confirmed maxillary sinusitis, cefdinir taken once or twice daily was as effective as amoxicillin-clavulanate given three times daily. Both drugs cleared pathogens at similar rates, and the once-daily cefdinir group actually had fewer people drop out because of side effects than either the twice-daily cefdinir or the amoxicillin-clavulanate group.² Another trial found that cefdinir achieved roughly a 90 percent cure rate, comparable to amoxicillin-clavulanate, with similar microbiological eradication.³

Cefdinir has also been tested against levofloxacin, a fluoroquinolone that sits in the highest efficacy tier. In a double-blind trial of patients with moderate-to-severe bacterial sinusitis, clinical cure rates were 83 percent for cefdinir and 86 percent for levofloxacin, a difference that was not statistically meaningful. The researchers concluded that cefdinir could serve as a suitable alternative to fluoroquinolones.⁴ Taken together, these trials and reviews consistently find that cefdinir performs on par with the standard regimens for acute bacterial sinusitis.⁵

What Makes Cefdinir Work Against Sinus Bacteria

Cefdinir is an oral third-generation cephalosporin, which means it belongs to the broader family of antibiotics that includes penicillin but has a wider reach against certain bacteria. One of its practical strengths is resistance to beta-lactamase, an enzyme that some bacteria produce to destroy older penicillin-type drugs.² That matters because H. influenzae and M. catarrhalis, two of the three main sinus infection culprits, frequently produce beta-lactamase.

Lab testing of bacteria collected from real patients shows cefdinir has strong coverage. Against H. influenzae, it had the highest susceptibility rates among the oral cephalosporins tested, ranging from about 97 to 99 percent. It showed complete or near-complete activity against M. catarrhalis. Against S. pneumoniae, results were more moderate, in the range of about 72 to 79 percent depending on the time period, though susceptibility improved over the years studied.⁶ That pneumococcal coverage gap is part of why cefdinir doesn’t quite match high-dose amoxicillin-clavulanate in predicted efficacy; amoxicillin at higher doses can overpower partially resistant pneumococcus in a way cefdinir may not.

The Penicillin Allergy Angle

One of the most common reasons a doctor prescribes cefdinir for a sinus infection is that you’ve reported a penicillin allergy, which takes amoxicillin and amoxicillin-clavulanate off the table. Many patients worry about cross-reactivity between penicillins and cephalosporins, and the concern is understandable since both belong to the beta-lactam family. But the risk is much lower than people assume, and it depends on which generation of cephalosporin you’re talking about.

A meta-analysis of allergy studies found that first-generation cephalosporins did carry a significantly higher risk of allergic reactions in penicillin-allergic patients, but second-generation cephalosporins showed no meaningful increase, and third-generation cephalosporins like cefdinir actually showed a trend toward lower risk. The analysis pointed to the chemical side chains as the real driver of cross-reactivity rather than the shared core structure, so two drugs that look structurally different in their side chains are unlikely to trigger the same allergic response.⁷ For most people with a history of a penicillin rash (not anaphylaxis), cefdinir is considered a safe choice. If you’ve ever had a severe anaphylactic reaction to penicillin, though, talk to your doctor before taking any cephalosporin.

Side Effects You Should Know About

Cefdinir is generally well tolerated. Across clinical trials in both adults and children, diarrhea was the most common complaint. The rate of diarrhea tended to be somewhat higher with cefdinir than with comparison antibiotics, but it was rarely severe enough to make patients stop treatment; discontinuation rates due to side effects were similar across groups.⁸ Other common side effects include nausea, headache, and vaginal yeast infections, which are typical of oral cephalosporins as a class.

There is one quirky side effect that catches parents off guard. If you or your child take cefdinir while also consuming iron-fortified formula, iron supplements, or iron-rich vitamins, the stool can turn a striking reddish or maroon color. This happens because cefdinir or one of its breakdown products binds to iron in the gut, forming a harmless but alarming-looking compound. It is not blood, and it does not mean anything is wrong.⁹ Separating the cefdinir dose from iron-containing products by a couple of hours can minimize the effect, though it doesn’t always prevent it entirely.

A Less-Known Risk Worth Considering

One risk that doesn’t get enough attention is Clostridioides difficile infection, a potentially serious gut infection caused by antibiotic-driven disruption of normal intestinal bacteria. A large U.S. study analyzing community-acquired C. difficile cases from 2008 to 2020 found that cefdinir carried one of the highest risks of triggering this infection among commonly prescribed outpatient antibiotics. Compared to doxycycline (used as a low-risk reference), cefdinir’s risk was nearly six times higher, placing it behind only clindamycin. Cefuroxime and fluoroquinolones also carried elevated risk, but cefdinir outpaced both.¹⁰

For a young, otherwise healthy person taking a short course for a single sinus infection, this risk is still quite low in absolute terms. But for older adults, anyone with a history of C. difficile, or people who have had multiple rounds of antibiotics recently, it’s a factor that could tip the choice toward a different drug. It’s also a good reason not to use cefdinir casually or for infections that probably don’t need an antibiotic at all, like the vast majority of sinus infections that are viral.

Once a Day or Twice a Day

Cefdinir is approved at 600 mg once daily or 300 mg twice daily for adults, and pediatric doses are weight-based. The once-daily option is a significant convenience advantage over amoxicillin-clavulanate, which typically requires two or three doses per day. For a parent trying to get a reluctant child to take medicine or an adult juggling a busy schedule, fewer doses can mean better adherence and a better chance the full course gets completed.

That said, an in vitro study comparing the two schedules against common respiratory pathogens found that twice-daily dosing was more effective at achieving deep bacterial killing and preventing regrowth over 24 hours.¹¹ That finding came from a lab model rather than a clinical trial with patients, so its real-world significance for sinus infections specifically isn’t certain. The large clinical trial comparing once-daily and twice-daily cefdinir in sinusitis patients found both were therapeutically effective, though the twice-daily arm didn’t quite match amoxicillin-clavulanate clinically while the once-daily arm performed comparably.² In practice, many clinicians will choose the schedule based on the patient’s situation: once daily for someone likely to miss doses, twice daily for a more serious or stubborn infection.

An Unexpected Advantage for Nasal Bacteria

Beyond simply killing the bacteria causing the acute infection, there’s evidence that cefdinir has a subtler beneficial property compared to broader-spectrum alternatives. Two studies looked at what happens to the bacteria living in the nasopharynx (the area behind the nose and above the throat) after treatment. One study found that after therapy, patients treated with cefdinir had significantly fewer pathogenic bacteria remaining in the nasopharynx compared to those treated with amoxicillin, and fewer of the surviving bacteria were penicillin-resistant.¹²

A follow-up study tracking patients for two months after treatment found something even more interesting. Both cefdinir and amoxicillin-clavulanate reduced pathogenic bacteria by similar amounts immediately after treatment, but pathogenic bacteria bounced back much faster in the amoxicillin-clavulanate group. The reason appears to be that cefdinir did a better job sparing the harmless “interfering” bacteria that naturally crowd out pathogens. After amoxicillin-clavulanate, those protective bacteria were decimated, dropping from 54 isolates before treatment to only 13 immediately after. After cefdinir, the protective flora went from 59 to 39, preserving a much larger population. The effect persisted for at least two months, with the cefdinir group maintaining significantly higher levels of these protective organisms.¹³ The practical takeaway is that cefdinir may leave you somewhat better protected against re-infection after treatment ends, because your nose still has its natural defensive bacteria intact.

When Cefdinir Probably Isn’t the Right Call

For moderate-to-severe bacterial sinusitis, or for anyone who has recently taken antibiotics, guidelines push toward higher-tier drugs. High-dose amoxicillin-clavulanate becomes the recommended choice for children who have received antibiotics within the past four to six weeks or whose symptoms are more than mild.¹ The logic is straightforward: recent antibiotic exposure increases the chance that surviving bacteria are partially resistant, and you need a drug with enough firepower to overcome that resistance.

Chronic sinusitis is a different condition altogether, and cefdinir’s role there is limited. A case series described a patient with recurring sinusitis who was treated with cefdinir and doxycycline together but continued to have purulent drainage, sinus pressure, and inflamed turbinates. That patient eventually needed a switch to a different antibiotic class entirely.¹⁴ Chronic and recurrent sinusitis often involves biofilms, mixed bacterial populations, and sometimes anatomical issues that oral antibiotics alone can’t fully address. If your sinus infections keep coming back despite treatment, the problem usually isn’t which antibiotic you’re on; it’s that antibiotics alone may not be enough.

Most Sinus Infections Don’t Need Antibiotics at All

Before you fill that prescription, it’s worth stepping back. The overwhelming majority of sinus infections are caused by viruses, and antibiotics do nothing for a virus. Guidelines generally recommend waiting at least seven to ten days after symptom onset before starting antibiotics, unless symptoms are severe (high fever, facial pain, purulent discharge lasting more than three or four days) or clearly worsening after an initial improvement. Nasal saline rinses, decongestants, and over-the-counter pain relievers handle most cases while the body fights off the virus on its own.

When antibiotics are warranted, the decision tree is essentially: amoxicillin or amoxicillin-clavulanate as first-line, cefdinir and other second-tier cephalosporins for penicillin-allergic patients or as an alternative first choice in mild cases, and fluoroquinolones or injectable ceftriaxone reserved for treatment failures or more complicated infections. Your doctor might also choose cefdinir simply because you can tolerate it well and will actually finish the course, which matters more than a few percentage points of theoretical efficacy if you’d skip doses of a drug that upsets your stomach.

Cefdinir for Kids

Cefdinir has a particularly strong niche in pediatric sinusitis treatment. It’s approved for use in children six months and older and comes in a strawberry-flavored liquid suspension that most kids accept without a fight. As noted in treatment guidelines, when a child has a penicillin rash history and needs a sinus infection treated, cefdinir is specifically preferred among the cephalosporin options because of that acceptance factor.¹ Getting a young child to take ten days of antibiotics reliably is a genuine challenge, and a drug that tastes decent and can be given once daily has a real-world advantage over something more potent that ends up spit across the kitchen floor.

Parents should know about the red stool phenomenon described earlier, since iron-fortified formula and children’s vitamins are common in the age group that takes liquid cefdinir. It can also be helpful to know that the efficacy tiers in children mirror those in adults: cefdinir sits in the 82 to 87 percent predicted efficacy range, and high-dose amoxicillin-clavulanate leads at 91 to 92 percent.¹ For a first mild episode, that gap is small enough that convenience and tolerability can reasonably factor into the choice.

How Cefdinir Compares to Newer and Stronger Options

Fluoroquinolones like levofloxacin and moxifloxacin are more potent on paper, but they carry their own serious baggage. The FDA has issued black box warnings about fluoroquinolone-associated tendon rupture, nerve damage, and central nervous system effects, and current guidance generally reserves them for situations where safer alternatives won’t work. Since cefdinir performs comparably to levofloxacin in head-to-head sinus infection trials with fewer serious safety concerns, it represents a reasonable middle-ground drug: broader than plain amoxicillin, safer than fluoroquinolones, and well tolerated enough that patients complete their courses.⁴

Cefdinir is approved for several other community-acquired infections beyond sinusitis, including pneumonia, bronchitis flare-ups, ear infections, throat infections, and skin infections.¹⁵ That versatility means your doctor may be quite familiar with it and comfortable using it across a range of respiratory infections. It also means cefdinir gets prescribed a lot, which is part of why its association with C. difficile risk is something the infectious disease community has started paying closer attention to. As with any antibiotic, the best use of cefdinir is a targeted one: prescribed when a bacterial sinus infection is genuinely likely, at the right dose, for the right duration, and not as a just-in-case measure for what is probably a cold.